Literature DB >> 7497597

Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.

B C Hüsken1, J de Jong, B Beekman, R C Onderwater, W J van der Vijgh, A Bast.   

Abstract

Cancer therapy with the anthracycline doxorubicin (Dox) is limited by cardiomyopathy, which develops in animals and patients after cumulative dosing. Generation of free radicals by Dox may be involved in this cardiotoxicity. Dox binds strongly to metal ions, especially iron(III). This Dox-metal complex stimulates the generation of free radicals through self-reduction of the complex. We investigated the possibility of inhibiting Dox-induced cardiotoxicity by scavenging of free radicals and/or chelating metal ions. The effects of Dox, both alone and in combination with iron-chelating agents, were studied on inotropy of the isolated mouse left atrium, lipid peroxidation (LPO) in cardiac microsomal membranes, ferricytochrome c (cyt.c3+) reduction, and oxygen consumption. The flavonoids 7-monohydroxyethylrutoside (mono-HER) and 7,3',4'-trihydroxyethylrutoside (tri-HER) and the ethylenediaminetetraacetic acid (EDTA) analogue ICRF-198 and its precursor ICRF-187 were used as iron-chelating agents. The latter were used for comparison since ICRF-187 has been reported to inhibit the cardiotoxic effects of Dox both in vitro and in vivo. Only the flavonoids could inhibit the negative inotropic effect of Dox (35 microM) on the mouse left atrium; in the presence of tri-HER (500 microM) the beating force decreased by 18% instead of 50%, whereas mono-HER completely prevented the Dox-induced negative inotropic effect. ICRF-198 and both flavonoids (500 microM) completely inhibited Dox (35 microM)-induced LPO, whereas ICRF-187 provided 65% inhibition. The observation that both cyt.c3+ reduction and oxygen consumption induced by the Dox-iron(III) complex (50/16.6 microM Dox3Fe3+) could be inhibited by superoxide dismutase proved the involvement of superoxide anions (O2-.). The iron-chelating agents (50 microM) inhibited cyt.c3+ reduction by 91% (mono-HER), 43% (tri-HER), and 100% (ICRF-198). Only mono-HER and ICRF-198 (50 microM) were capable of inhibiting the oxygen consumption by 70% and 43%, respectively. It is concluded that flavonoids offer a good perspective for further studies on the prevention of Dox-induced cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7497597     DOI: 10.1007/bf00685629

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  37 in total

Review 1.  Metabolism and reactions of quinoid anticancer agents.

Authors:  G Powis
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

2.  Free radical formation from anthracycline antitumour agents and model systems--I. Model naphthoquinones and anthraquinones.

Authors:  N J Dodd; T Mukherjee
Journal:  Biochem Pharmacol       Date:  1984-02-01       Impact factor: 5.858

3.  Transfer of ferritin-bound iron to adriamycin.

Authors:  E J Demant
Journal:  FEBS Lett       Date:  1984-10-15       Impact factor: 4.124

4.  Experimental animal models of adriamycin cardiotoxicity.

Authors:  J H Doroshow; G Y Locker; C E Myers
Journal:  Cancer Treat Rep       Date:  1979-05

5.  Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex.

Authors:  J M Gutteridge
Journal:  Biochem Pharmacol       Date:  1984-06-01       Impact factor: 5.858

6.  Reduction of O2 by iron-adriamycin.

Authors:  J L Zweier
Journal:  J Biol Chem       Date:  1984-05-25       Impact factor: 5.157

7.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

8.  Effect of anthracycline antibiotics on oxygen radical formation in rat heart.

Authors:  J H Doroshow
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

9.  Protection against lipid peroxidation by a microsomal glutathione-dependent labile factor.

Authors:  G R Haenen; A Bast
Journal:  FEBS Lett       Date:  1983-08-08       Impact factor: 4.124

Review 10.  Flavonoids, a class of natural products of high pharmacological potency.

Authors:  B Havsteen
Journal:  Biochem Pharmacol       Date:  1983-04-01       Impact factor: 5.858

View more
  5 in total

Review 1.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 2.  The role of antioxidants in the era of cardio‑oncology.

Authors:  Duncan T Vincent; Yasmine F Ibrahim; Michael Graham Espey; Yuichiro J Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  2013-12       Impact factor: 3.333

Review 3.  Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.

Authors:  Diana Iarussi; Paolo Indolfi; Fiorina Casale; Vincenzo Martino; Maria Teresa Di Tullio; Raffaele Calabrò
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 4.  Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 5.  Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity.

Authors:  Donato Cappetta; Antonella De Angelis; Luigi Sapio; Lucia Prezioso; Michela Illiano; Federico Quaini; Francesco Rossi; Liberato Berrino; Silvio Naviglio; Konrad Urbanek
Journal:  Oxid Med Cell Longev       Date:  2017-10-18       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.